血液透析療法中慢性腎不全合併C型肝炎ウイルス感染症に対するOmbitasvir/Paritaprevir/Ritonavir療法の効果  [in Japanese] Effects of Ombitasvir/Paritaprevir/Ritonavir Therapy on HCV infection in patients with chronic renal insufficiency on hemodialysis  [in Japanese]

Access this Article

Search this Article

Author(s)

    • 安部井 誠人 Abei Masato
    • 住吉クリニック病院内科|筑波大学医学医療系消化器内科 Division of Gastroenterology, Sumiyoshi Clinic Hospital|Division of Gastroenterology, University of Tsukuba
    • 山田 武史 Yamada Takeshi
    • 住吉クリニック病院内科|筑波大学医学医療系消化器内科 Division of Gastroenterology, Sumiyoshi Clinic Hospital|Division of Gastroenterology, University of Tsukuba

Abstract

<p>HCV often infects patients with chronic renal failure (CRF) on hemodialysis (HD) and significantly affects the prognosis of these patients. Recently, HCV treatment has been revolutionized by the new generation of direct-acting antivirals (DAAs) which offers short, IFN-free, highly efficacious, well-tolerated curative therapies, but data are limited on the efficacy of these therapies for HCV infection in patients with CRF on HD. Aim: We examined the efficacy and safety of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir combination therapy in 9 patients with CRF on HD and chronic HCV infection. Patients and Methods: Nine patients with CRF on HD and untreated HCV genotype 1 infection were treated with OBV/PTV/r combination therapy for 12 weeks. Results: All 9 cases completed the 12 weeks therapy and serum HCV-RNA became negative after 4 weeks of the therapy and continued to be negative even 12 weeks after the therapy in all cases (SVR12, 100%). Serum ALT values were normalized in all cases. Calcium channel blockers (CCB), which had been taken by 5 cases, were required to change to other anti-hypertensive drugs considering that CCB causes hypotension due to drug-drug interactions with ritonavir, but all adverse events were mild or moderate in this study.</p><p>Conclusion: The combination therapy of Ombitasvir, Paritaprevir, Ritnavir for 12 weeks in 9 CRF patients on HD with HCV infection was well tolerated and highly effective (SVR12, 100%).</p>

Journal

  • Kanzo

    Kanzo 57(10), 565-567, 2016

    The Japan Society of Hepatology

Codes

  • NII Article ID (NAID)
    130005276891
  • NII NACSIS-CAT ID (NCID)
    AN00047770
  • Text Lang
    JPN
  • ISSN
    0451-4203
  • NDL Article ID
    027673272
  • NDL Call No.
    Z19-130
  • Data Source
    NDL  J-STAGE 
Page Top